Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,788.00-1.91%ETH$2,478.56-3.77%GOLD$4,172.90+0.38%OIL$91.02-0.51%
Smart Investors Daily
SID Premium
OC

NASDAQ · OCS

Oculis Holding AG

Healthcare · Biotechnology

$8.66

Up+$0.16 (+1.88%)

Updated Oct 9, 2026, 2:45 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.09B
P/E ratio
-8.07
Dividend yield
0.00%
52-week range
$8.30 – $34.48
Volume
452.01K
Avg. volume
99.02K

Price performance · OCS

OCS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

OCS closed at $8.66 after 21 trading sessions, down 23.43% for the selected period.

Last close
$8.66
Period change
-23.43%
Period low
$8.50
Period high
$11.31
Daily close
View OHLC price history
OCS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$8.50$8.75$8.37$8.66452.01K
Oct 7, 2026$8.83$8.83$8.35$8.50173.69K
Oct 6, 2026$8.61$8.80$8.30$8.72291.65K
Oct 5, 2026$8.79$9.00$8.56$8.56242K
Oct 2, 2026$8.82$8.8254$8.53$8.73586.3K
Oct 1, 2026$9.16$9.26$8.67$8.76578.45K
Sep 30, 2026$9.20$9.48$9.02$9.34434.74K
Sep 29, 2026$9.10$9.38$9.07$9.13373.46K
Sep 28, 2026$9.20$9.33$9.00$9.06266.99K
Sep 25, 2026$9.71$9.71$9.10$9.27239.61K
Sep 24, 2026$9.94$9.945$9.21$9.41209.25K
Sep 23, 2026$10.64$10.77$9.88$9.99143.77K
Sep 22, 2026$10.27$10.84$10.26$10.71206.77K
Sep 21, 2026$10.19$10.35$10.00$10.14201.83K
Sep 18, 2026$10.17$10.43$9.67$10.14412.07K
Sep 17, 2026$9.90$10.155$9.85$9.98248.06K
Sep 16, 2026$10.11$10.1999$9.65$9.91314.1K
Sep 15, 2026$10.60$10.61$10.00$10.07159.31K
Sep 14, 2026$10.56$10.835$10.51$10.60153.19K
Sep 11, 2026$11.39$11.98$10.50$10.56226.62K
Sep 10, 2026$11.34$11.60$11.00$11.31169.33K

Latest OCS news

The latest Smart Investors Daily articles mentioning OCS.

Stock researchCompany · Overview

OCS research

Overview

Company profile and research snapshot.

Company profile

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.50
Implied upside
—
Analysts
—
OCS recent ratings
DateFirmRatingTarget
Sep 18, 2026HC Wainwright & Co.Buy—
Aug 14, 2026JP MorganOverweight—
Aug 5, 2026HC Wainwright & Co.Buy—
Jun 3, 2026JP MorganOverweight—
Jun 2, 2026BairdOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculi

Yahoo · Oct 1, 2026

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry part

Yahoo · Sep 30, 2026

Oculis Announces Resignation of Lionel Carnot from Board of Directors

ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017. Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the B

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By